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I. INTRODUCTION
Drug design means many things to many people. Commercially the aim is the
development of compounds that can be patented and meet a variety of regulatory
standards. In drug design, for medical purposes, toxicity and bio-availability are
major considerations. Synthetically, questions related to ease of synthesis and
chemical stability may dominate. From a physical perspective drug design is seen
primarily as the process of optimizing specific (bio)mplecular interactions. The
biological activity of any compound can essentially be considered as a series of
independent binding, transport and processing events. These events begin when
the compound enters the body and end when it is either metabolized or excreted.
Thermodynamically and kinetically each of these events may be expressed in
terms of changes in free energy. The difference in free energy will determine how
the compound partitions between different environments or between reactants
and products and the intervening free energy barrier will determine the rate of
such partitioning. Therefore, from a theoretical biophysical viewpoint drug
design is concerned primarily with the estimation of the change in free energy for
compounds in different environments. Most frequently it will be the difference
between the free energy of a compound in water compared to that of the same
compound bound to a specific protein receptor site that is of interest.
Alternatively, it might be the difference in free energy of a compound bound to a
bacterial or a mammalian form of the same enzyme. It may, however, correspond
to the difference in free energy of a compound in an oxidizing or reducing intra-
cellular environment where no specific macromolecular receptor can be identified.
An example of such a case may be anti-cancer drugs designed to accumulate
preferentially in rapidly metabolizing cells.
Free energy is a global property of a system and it is this that gives rise to the
essential computational difficulty in drug design. Quantum mechanically, the
Helmholtz free energy, F, of a system of N particles in a volume F a t a
temperature T, in terms of the canonical partition function, Q, is given by,
= -kBTlnQ(N,V,T)
E i N V ) / l T
 ( i )
where the energy of a quantum mechanical state, j , of the system is given by
Ej(N, V), and kB is Boltzmann's constant. The total free energy of a system is thus
dependent on all possible electronic and nuclear degrees of freedom.
For any realistic system the absolute free energy cannot be calculated. It is only
ever possible to estimate the change in free energy between two systems and then
only by evoking a large number of often very crude assumptions or empirical
Abbreviations. CNDO, Complete Neglect of Differential Overlap; COMFA, Comparative Molecular
Field Analysis; DNA, deoxyribose nucleic acid; HOMO, Highest Occupied Molecular Orbital; LFER,
Linear Free Energy Relationship; LUMO, Lowest Unoccupied Molecular Orbital; MC, Monte Carlo;
MD, molecular dynamics; MEF, Molecular Electric Field; MEP, Molecular Electrostatic Potential;
QSAR, Quantitative Structure Activity Relationship; SAR, Structure Activity Relationship.
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approximations. The relevant question for any given drug design problem is, for
which sets of assumptions or approximations will the estimate of the change in free
energy be useful ? The answer will depend on the nature of the system, the amount
of structural information available, the relative importance of quantum
mechanical effects, the degrees of freedom in the system that can be safely ignored
and the nature of the biological data against which the results can be compared.
This review aims to provide a broad overview of the range of methodologies that
can be used to estimate relative free energies in drug design. The focus is not on
applications, but on the physical bases of the methodologies, the assumptions on
which they are based and the conditions under which such assumptions are valid.
The primary purpose is to enable the reader to assess the applicability of a given
class of methods to tackle a specific problem. Specific methods are only discussed
by way of example. We do not aim to be encyclopaedic. Despite the fact that
empirical methods currently dominate drug design the review is also intentionally
biased toward the use of explicit free energy calculations based on detailed
structural information. This bias merely reflects the fact that as the cost of
computational resources falls the trend toward potentially more accurate explicit
methods will be inevitable.
2. DRUG DESIGN BASED ON LEAD COMPOUNDS
All structure based drug design methods aim to derive a relationship between the
topology or properties of a given molecular structure and a specific biological
activity. Where the precise target or action of a lead compound is not known, such
structure activity relationships (SAR's) must be derived empirically. The aim is to
obtain a set of mathematical relationships between the properties of a set of related
structures which form a given training set and some measure of biological activity
that can later be used in a quantitative fashion to predict the activity of novel
compounds (QSAR). In principle any physico-chemical or derived property that
varies systematically in the series of test compounds can form the basis of a QSAR
study.
The literature relating to the use of empirical methods in specific drug design
studies is immense. A number of excellent general reviews exist (Martin, 1978;
Franke, 1984; Martin, 1991; Silverman, 1992; Kubinyi, 1993) and it is not our
intention to repeat the exercise here. Instead we wish to address the question of
why certain molecular properties frequently show simple correlations to a variety
of biological activities and under what conditions the assumptions that are evoked
to account for such correlations might hold.
2.1 Classical quantitative structure activity relationship (QSAR) approaches
A century ago it was recognized that the narcotic effect of a series of neutral
compounds appeared to be a function of their oil :water partition coefficient, P.
Subsequently, the biological activity within many series of related compounds was
shown to depend in a simple manner on the free energy of transfer from water to
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a variety of organic phases given by the logarithm of the partition coefficient, log
P. The basic assumption inspired by such studies was that the organic phase
mimicked the interaction of the compounds with their site of action in biological
membranes (Martin, 1978).
Modern QSAR studies stem, however, from work on the effects of sterically
remote substituents on the rates of organic reactions which led Hammett
(Hammett, 1940) to propose SAR's based on an empirical electronic parameter, cr,
defined as
kxlog-r- = p<rx (2)
where k0 is the rate or equilibrium constant of a reference compound, kx the
constant for the compound containing the substituent X and p is a proportionality
constant characteristic of the sensitivity of the reference compound to substitution
at a specific site. Taft (1956) extended the work of Hammett to include an
additional parameter, Es, defined in an analogous manner to the electronic
parameter cr, to account for steric effects such that
log-£ = pax + 8E. . (3)
where 8 is again a system dependent scaling parameter analogous to p. The
approach illustrated by the work of Hammett and Taft was generalized by Hansch
and coworkers (Hansch et al., 1963; Fujita et al., 1964; Hansch & Fujita, 1964)
who proposed a group hydrophobicity parameter, n, defined in an analogous
manner to tr and Es based on octanol: water partition coefficients and introduced
the assumption that the effects of the steric, electronic and hydrophobic properties
of a given molecule on biological activity were independent and additive. This led
to the general principle of linear free energy relationships (LFER's) where the
activity, A, or the inverse of the effective concentration, i/C, could be expressed
as
log A = fh(xh) +/,(*,) +/,(*,) + constant .(4)
in which the log of the activity (a free energy) is assumed to be a linear
combination of independent functions describing the hydrophobic, h, electronic,
e, and steric, s, properties of a given compound. The functions,/(#), are frequently
assumed to be linear but may in principle take any form. Also, it should be noted
that although originally expressed in terms of n, <r and Es a myriad of other
physical and derived parameters have been used in different QSAR studies
(Franke, 1984).
LFER's and QSAR studies have proven to be very useful. From a physical
perspective, however, it is not clear why LFER's should hold or what can be
inferred in regard to the particular system when they do hold. The simplest type
of biological activity is the direct binding of a test compound to an isolated
receptor. In this case log A is directly proportional to the free energy of binding.
Free energy is a global property of a system and cannot formally be separated into
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a sum of components or group contributions unless the interactions on which the
separation is based are either uncorrelated or purely enthalpic (van Gunsteren et
al. 1993). For the interaction of specific substituents with specific residues of a
receptor protein this will most likely not be the case. In contrast, in whole body
or cellular assays the measured activity may reflect a sequence of uncorrelated
transport and recognition events. The value of log Poctanoi.water might then reflect
the rate of transport through the membrane and the oxidation potential of the
compound its reactivity within the cell. In this case the application of (2) may well
be valid.
The difficulty in assigning group free energies for use in QSAR studies can be
illustrated in relation to the group hydrophobicity parameters of Hansch. Hansch
defined the hydrophobicity nx of a given substituent X as
TT
 x = \ogPx-log PH (5)
where Px and PH are the octanol: water partition coefficients of a compound
containing the substituent X and a hydrogen atom respectively. Octanol is often
chosen as a reference solvent as, due to the presence of hydroxyl groups, it is
assumed to approximate the hydrogen bonding environment of a biological
membrane or protein. In the series of substituted aromatic compounds initially
investigated by Hansch and coworkers specific n values were, in the absence of
strong electronic effects, shown to be constant and additive. Hydrophobicity is,
nevertheless, an essentially entropic phenomenon (Tanford, 1973). In this respect
the additivity of n values is surprising. Both phases are, however, liquid. The
nature of the local solvent environment in which the substituent is inserted, and
hence the associated change in entropy, will depend primarily on the nearest
neighbour atoms. For a series of aromatic parent compounds the nature and
spatial arrangement of the neighbouring atoms is essentially constant. As
expected, different hydrophobicity parameters or the use of correction terms are
required for the same substituents attached to aliphatic chains or in close
proximity to groups that perturb the local solvent environment. Using a variety of
approaches log P values can be empirically predicted with high accuracy (Suzuki
& Kudo, 1990). It is to be expected, however, that the use of group
hydrophobicity parameters is more appropriate in liquid-like rather than highly
structured environments.
2.2 Empirical methods incorporating spatial information
The interaction of a given compound with a specific receptor site will depend not
only on the physical properties of the isolated substituents but also on their spatial
arrangement. Crude spatial indices such as the steric parameters of Verloop et al.
(1976), can be used to describe the volume and shape of a given substituent but
such measures do not explicitly incorporate conformational information. To
include explicit spatial information assumptions in regard to the active
conformation and the mutual alignment of the test compounds must be made. In
the distance geometry approach of Crippen (Crippen & Havel, 1988) such model
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dependencies are minimized by considering only distances between atoms or
interaction sites. Sets of distance bounds describing the conformational flexibility
of each of the test compounds are generated. A comparison of the test compounds
is then made based on the assumption that there is a single active conformation or
pharmacophore. Sets of interaction sites are defined and geometrically allowed
binding modes for each of the test compounds are evaluated. A simple scoring
function based on favourable and unfavourable interactions with these sites can
then be used to correlate structural features with some measure of biological
activity (Ghose & Crippen, 1985). Alternatively, the ensemble of test compound
configurations weighted by some measure of biological activity can be used to
extract a set of common distances between potential interaction sites in order to
define a potential pharmacophore or pseudo binding site (Sheridan et at. 1986).
Although defining such a consensus binding site may be helpful in proposing
alternate test compounds, it does not necessarily bear any relationship to a
physical binding site with which the compounds under investigation might
interact. This is especially true if the biological data with which it is correlated has
not been derived from binding studies using an isolated receptor. Distance
geometry and other 3D-QSAR methods depend strongly on the assumption that
chemically related structures bind in a similar conformation and in the same
orientation to a given receptor. While for simple rigid molecules this generally
may be a very good assumption, it is certainly not always the case, as illustrated
by three closely related elastase inhibitors which not only show different binding
modes, but interact with different subsites (Mattos et al. 1994).
Distances between interaction sites is only one of a number of measures of
molecular shape or molecular similarity that have been used to incorporate
conformational information into QSAR studies. Other indices include steric
volume overlap, charge matching and atom pair matching (Hopfinger & Burke,
1990). Similarity indices based on quantum mechanical calculations are discussed
in the next section. Similarity indices discriminate on the basis of molecular
conformation. Thus, results from such comparisons will depend on the model
used to generate the three-dimensional structure of the test compounds.
Structures can be generated using knowledge based approaches such as the
programs CONCORD or WIZARD (Rusinko III et al. 1988; Leach et al. 1990),
or minimum energy configurations from quantum mechanical or empirical force
field calculations can be used. Similarity indices have also been derived as
trajectory averages from molecular dynamics simulations. As with distance
geometry methods it is assumed that there is a single active conformation and test
compounds are superimposed on a given reference compound before comparison.
This inevitably leads to a dependence on the choice of reference compound and
the superposition criteria.
In the comparative molecular field analysis (CoMFA) method of Cramer III et
al. (1988) molecules in a given test series are again aligned on a chosen parent
structure. The potential energy with respect to a given force field is then sampled
in the space surrounding each molecule using a regularly spaced grid and
correlated at each point with a measure of biological activity. The correlation is
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performed using the partial least squares method developed by Wold and co-
workers (Wold et al. 1984) with cross-validation to give some measure of the
predictive ability of the potential energy at each grid point. The result can then be
expressed as a 3-dimensional contour surface reflecting the relationship between
the molecular field and a specific biological activity.
CoMFA analysis is in general performed using the non-bonded terms from
classical molecular mechanics force fields. The implementation in the molecular
modelling package SYBIL standardly uses a 6-12 van der Waals and a Coulomb
potential energy function, the latter with a distance dependent dielectric. The
potential energy is calculated with respect to a probe atom. Although Cramer et
al. (1988) initially used parameters for an sp3 hybridised carbon atom carrying a
charge of + 1, the choice of probe atom and charge is essentially arbitrary and may
be varied in order to optimize the correlation to a given set of experimental data.
The use of such a pseudo physical force field has, however, led to ambiguities in
the manner in which results from such studies should be interpreted. Specifically,
there are questions remaining about whether the potential energy surface
generated in the analysis reflects the structure of a specific receptor and whether
the use of such a potential limits the analysis to purely enthalpic effects.
Interaction energies obtained from static modelling with classical molecular
mechanics force fields can at best only indicate enthalpic contributions to binding.
It has been argued, therefore, that a CoMFA study using a potential energy
function expressed purely in terms of van der Waals and Coulomb interactions
cannot be expected to correlate with entropically driven phenomena or atom type
specific interactions such as hydrogen bonding without the inclusion of special
terms. In practice, inclusion of hydrophobic potentials (Kellogg et al. 10.91)
and/or an explicit hydrogen bonding term using for example the GRID potential
energy function (Goodford, 1985; Kim, 1991) does not necessarily improve the
overall correlation (Folkers et al. 1993; Kim et al. 1993). As an empirical method
CoMFA is not limited to the use molecular mechanics force fields (Waller &
Marshall, 1993). Conversely, the use of such force fields to extract correlations
should not be confused with calculation of interaction energies based on the
structure of the ligand-receptor complex. This was illustrated in a recent study of
Klebe & Abraham (1993). Using crystallographic data to align a series of
endothiapepsin inhibitors they demonstrated a significantly better correlation to
enthalpic changes on binding than to entropy or free energy changes using a van
der Waals and Coulomb potential energy function. The alignment correctly
represented the binding to the receptor. Since the enthalpic changes were large
and as enthalpic changes can be both formally separated into atomic contributions
and equated to interaction energies, this result is not surprising. Fitted to free
energies, however, the correlations generated by CoMFA can neither be used to
infer interaction energies nor be expected to reflect details of the actual receptor.
In the same study Klebe and Abraham observed for inhibitors of thermolysin that
alignment based on crystallographic data yielded substantially inferior
correlations to free energy data than two alternative alignment procedures. Where
the activity data relates not to receptor studies but to cell or organ assays any
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inferences drawn in regard to a specific receptor site from the generated
correlations are even less reliable. In summary, although the potential energy
terms commonly used in CoMFA have been derived in relation to detailed 3-
dimensional structural information they are used in such studies simply as
parameters. In this way the combination of potential energy terms from different
sources, truncation or scaling of specific interactions, and fitting to non-linear
functions can all be justified. In doing so, however, the biophysical basis of the
force field is largely lost.
2.3 Empirical methods based on the calculation and comparison of molecular
quantum mechanical and electrostatic properties
Quantum mechanical methods permit the calculation of a large number of
molecular properties that can be empirically related to the action of a drug
molecule. Quantum mechanical calculations can indicate preferred
conformations, the distribution of charge within a molecule, possible tautomeric
states, and potentially reactive functional groups (Richards, 1983). Such
calculations are nowadays fairly routine with semi-empirical and ab initio
quantum mechanical packages (for example Frisch et al. 1992; Stewart, 1990) and
are very often the first step in understanding the behaviour and action of a
potential drug molecule. Due to computational limitations and the fact that the
relevant environment in which the molecule acts or the receptor to which it binds
is often unknown many approximations must be made. Most commonly the
calculations are performed in vacuo or alternatively in a dielectric continuum
whose permittivity reflects that of the proposed environment. Alternatively a
supermolecule calculation can be performed in which a few atoms of the
environment (solvent molecules, amino acid residues etc.) are placed to mimic, at
least approximately, the perturbing effect of the surroundings. The accuracy of
quantum mechanical calculations is also limited by the number of electrons in the
molecule which itself places limitations on the size of basis set that can be used
(Hehre et al. 1986). Given that the relationship between the drug molecule's
behaviour in isolation and at a receptor is uncertain, the use of the highest levels
of theory incorporating large basis sets and electron correlation is not usually
warranted. In cases where a whole range of molecules is systematically being
studied such extensive calculations would in any case be prohibitively expensive.
Calculations based on the quantum mechanical or electrostatic properties of
molecules tend to ignore the entropic component of drug action, that is, the
underlying assumption is that enthalpic terms dominate the activity. Thus drug
design efforts are frequently aimed at maximizing binding capacity, particularly
through complementarity of properties for the ligand and host believed to be
involved in drug action (Dean, 1987).
2.3.1 Conformational energy
One of the most useful quantities that can be derived from quantum calculations
is the energy of the molecule and how this changes with conformation. This can
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give insights into the low energy conformations which the molecule might adopt
at the receptor or alternatively a range of conformations which may not have
minimal energy but which may be active and stabilized at the receptor. Such
calculations are usually performed by systematically changing all the dihedral
angles within the molecule, optimizing each structure and calculating the energy
for each conformation. In cases where there are too many such dihedral angles,
portions of the molecule are independently optimized and held rigid while
rotation about a few critical angles is performed. The resulting information,
namely the conformational energy, is usually contoured as a function of two
dihedral angles. Conformational free energies can also be determined, which
involve the additional calculation of vibrational frequencies for use in determining
the vibrational partition function. A reaction mechanism can be postulated and the
structure and energetics along a proposed reaction coordinate can be determined,
including identification of the transition state. This may be relevant to drug action
in cases where an enzyme is believed to stabilize the transition state of a reaction
and one is interested in designing a transition state mimic to block the reaction.
The energies of simple reactions in vacuum such as protonation and
tautomerism are straightforward to determine using quantum mechanical
calculations. Such calculations may indicate whether alternative structures or
protonation states are energetically feasible. The reactivity of a molecule can also
be investigated by visualizing the frontier orbital electron density (Fukui et al.
1952). Electron density in the HOMO (highest occupied molecular orbital) will,
in principle, indicate the position of electrophilic attack while for nucleophilic
attack the LUMO (lowest unoccupied molecular orbital) is of importance. In
order to compare frontier orbital electron density on different molecules the
concept of superdelocalizability has been introduced. Here the contribution to the
electron density from each molecular orbital is weighted by the energy of the
orbital.
2.3.2 Electron density
Given a lead compound one usually wishes to compare it with a potential drug
molecule so that the efficacy of the latter may be estimated. Perhaps the most
natural choice for a quantum mechanical property with which to compare
molecules is the electron density, p(r). This is the number of electrons per unit
volume and can be written in terms of the total molecular wavefunction V as
follows:
p(r) = N f... f I V(*i, *2 *Ar)lsd*i d*,.. • dxN. (6)
Here N is the total number of electrons of the system and x( = (s,,r,) are the spin
and space coordinates of electron i. Integration of p{r) over the whole space yields
the total number of electrons in the system. The electron density lies at the heart
of the currently fashionable density functional approaches to quantum chemistry
(Parr & Yang, 1989) which follow from the realization that p{r) determines the
ground state wavefunction of the system and thus all its electronic properties. The
electron density can also be expected to represent the underlying nuclear
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framework of the molecule since its overall electron density can essentially be
considered as the sum of spherical atomic electron densities with slight
deformations. Electron density is a useful concept with which to work since it can
be directly determined by experimental methods such as X-ray diffraction. The
electron density is straightforward to compute using both ab initio and semi-
empirical quantum mechanical programs. There are, however, limitations on the
size of molecule and the number of basis functions used in the calculation. Semi-
empirical methods can be used for a few hundreds of atoms while the highest
accuracy ab initio methods are restricted to an order of magnitude fewer atoms.
The easiest, and crudest, way of indicating the charge distribution within a
molecule is to calculate atom-centred partial charges. This is the net charge,
expressed in number of electrons, residing on an atom within a molecule and can
be calculated from quantum mechanical or more empirical methods. Because the
partial charge on an atom is not a physical quantity, i.e. it cannot be measured
experimentally and there is no associated quantum mechanical operator, many
methods of calculating it exist and assignment of charge is somewhat arbitrary.
However, the partial atomic charges can indicate (i) whether a given atom has
increased or decreased charge density relative to the unbound state and (ii) the
relative size of build-up or depletion of charge on different atoms within the
molecule. Inspection of a point charge distribution can indicate possible positions
of nucleophilic or electrophilic attack.
Visualization of electron density can enable qualitative comparisons between
molecules to be made. Very often two-dimensional contour plots are used to
represent electron density in various planes of the molecule. Alternatively
isodensity surfaces can be drawn around the molecules. These are sets of points
in three-dimensional space at which the electron density attains a certain pre-set
value, and are usually represented as a dot-surface, a triangulated mesh or an
interpolated smooth surface. This can be used as a descriptor of the shape or
surface of the molecule and can serve as a property to compare a given series of
molecules or to map out the shape of an unknown receptor. Conversely one can
define a certain molecular surface, such as the van der Waals or solvent-accessible
surface, and evaluate the electron density at points evenly scattered over the area.
The values of the electron density at these points can then be colour-coded to ease
visualization. One might also analyze the difference density using similar methods.
This is the difference between the molecular electron density and the density
obtained by superposition of unperturbed atomic densities. Isodensity surfaces of
the difference density clearly show how the electron distribution changes on
formation of the molecule and can thus highlight regions of enhanced or
diminished electron density. These may well be indicative of sites for electrophilic
or nucleophilic attack, and one might envisage that such regions will occur in
similar locations for molecules which bind to the same receptor and react by the
same mechanism.
While qualitatively the display of electron density for a series of molecules can
be instructive, to quantify the similarity between two molecular charge
distributions some form of simple index is required. Similarity indices can serve
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both as a criterion for the superposition of the molecules to aid in the mapping of
an unknown receptor and as a descriptor for QSAR studies. One such similarity
index was introduced by Carbo (Carbo et al. 1980). Given two molecules A and
B, with respective electron densities pA{r) and pB(r), then a measure of the
difference between the two densities is given by
J (7)
If both molecules remain rigid then only the last term of (7) varies as the relative
position of the molecules changes. Thus superimposing the molecules by
minimizing the difference of the charge densities corresponds to determining a
maximum for the integral jpA(r) pB(r) dr. Carbo proceeded to define a normalized
measure of similarity, rAB, given by
(8)
where rAB lies in the interval [0,1]. Molecules with complete similarity, pA{r) =
PBC*"). will have rAB = 1 while complete dissimilarity will be indicated by rAB = o.
This was originally implemented within a semi-empirical CNDO framework
although an improved ab initio formulation has been presented (Bowen-Jenkins et
al. 1985). The less accurate quantum mechanical methods tend to be less
discriminating than the more accurate ones, while the latter tend to be too
expensive for optimization of the similarity. This similarity measure is also very
dependent on the manner in which the molecules are superimposed. In the
presence of heavy atoms the similarity is dominated by their large electron density
close to the nucleus and small misalignment of such atoms can give rise to
unrealistically low similarity values. To overcome this problem use of only the
valence electron density has been proposed and found to give results more in tune
with chemical intuition.
The Carbo index of electron density similarity is not unique and while rAB is
sensitive to the shape of the electron density it is not sensitive to its magnitude.
For example, when pA(r) = npB(r) then rAB is still equal to unity indicating full
similarity. An alternative index, albeit in a different context, has been proposed by
Hodgkin (Hodgkin & Richards, 1987):
2\pA(r)pB(r)dr
* = (9)
sAB compares the shape of the electron density and also its magnitude. Given the
condition pA[r) = npB(r) then sAB = zn/(n2+ 1) and can thus distinguish between
the molecules. Despite valence-only calculations both indices still tend to be more
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sensitive to the positions of the nuclei than to the long-range valence electron
density. An innovative attempt to overcome this limitation was made by using
densities in momentum space, p(J>), rather than position space (Cooper & Allen,
1989). The alternative similarity index
2\pnpA(P)pBiP)dp
SAB(n) = i j , (10)
was introduced, in which p = \p\. This measure of similarity has a number of
advantages. Firstly, it is independent of the distance between the molecules in
position-space and so.many of the problems associated with the superposition of
the two molecules will be avoided. Secondly, p(p) is dominated by the valence
electrons, which have low p values, whereas p(r) is dominated by core-electrons
and thus the position of the nuclei. Furthermore, use of SAB(n) for n = —1,0,1,2
can be used to measure similarity between different regions of the electron density.
2.3.3 Electrostatic potential
A quantity that has perhaps received more attention than the electron density in
studies of molecules and in QSAR is the electrostatic potential, V(r), defined as
follows
The first term represents the contribution from the N atomic nuclei of charge {Z(}
situated at {Rf}, while the second term is the contribution from the electronic
charge density. V(r), often called the molecular electrostatic potential (MEP),
represents the energy of interaction between the molecule and a proton situated at
r, or if a point-charge of value q is situated at r the energy of interaction will be
given by qV(r). It should be stressed that the electrostatic potential is usually
calculated for an isolated molecule and so using qV(r) to evaluate an energy of
interaction is a first-order approximation, neglecting cooperative effects such as
polarization and charge transfer. However the MEP can be used to give a very
clear indication of the areas of three-dimensional space where groups of a given
charge will be attracted or repelled. One can thus use the MEP to map out the
surface of a pseudo receptor based on the assumption that the receptor will have
a complementary electrostatic potential to that of the ligand. Furthermore, by
comparing the MEP's for a number of ligands one can propose areas of the
molecules associated with binding to a receptor or possible areas for electrophilic
or nucleophilic attack. The electrostatic potential can be calculated in most ab
initio or semi-empirical quantum chemistry programs, although once again there
are limitations on the size of molecule that can be treated. Very often when
working with a large number of molecules or with very large molecules, such as
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proteins or DNA fragments, where a fully quantum mechanical treatment is not
possible, a point charge approximation is made and the following expression used
(^r) = —Si-%7 (12)
l R l
where {gj are the net atomic charges situated on the nuclei.
As with electron density one can introduce a similarity index with which to
compare molecular electrostatic potentials (Hodgkin & Richards, 1987). This can
be of the same form as expressions (8) or (9) with the electrostatic potential at
position r, V(r), replacing the electron density p(r). In their implementation
Hodgkin and Richards used a point charge model and evaluated the integrals
required for the calculation of the similarity index numerically on a grid.
Generally reasonable results could be achieved with a grid which extends ro nm
beyond the molecule and has a mesh of o-i nm. To avoid singularities associated
with the evaluation of the MEP at the nuclear sites the ' inside' of the molecule was
excluded from the calculation. Details associated with the grid extent and fineness,
the method used to optimize molecular geometry and obtain atomic charges have
been addressed (Burt et al. 1990) as too has the introduction of flexible fitting for
optimization of the similarity index (Burt & Richards, 1990). The use of a 2- or
3-Gaussian expansion for i/r (Good et al. 1992 a) allows the grid-based
determination of the electrostatic potential to be replaced by analytic evaluation
which makes the calculation two orders of magnitude faster. Furthermore more
robust methods of optimization can be used so that the fitting of molecules is less
likely to become stuck in local minima, and because there is no singularity at the
nucleus there is no need to exclude the molecular volume from the similarity
calculation. This method has been widely applied to the screening of results from
3D-database searches (Good et al. 19926) and to the calculation of similarity
matrices for use in QSAR studies (Good et al. 1993).
2.3.4 Electric field
A further molecular property of use in analysing and comparing structures is the
molecular electric field (MEF), defined as follows
*(r) = - V F ( r ) . (13)
The electric field is thus the negative of the gradient of the electrostatic potential
and as such is a vector quantity. The molecular electric field is usually considered
in two ways. Firstly, the scalar product #(r)-(i, where \i is a permanent dipole
moment of a second molecule, gives the energy of interaction of the dipole with
the field of the original molecule. Such interactions can be important in the
binding of a ligand to a receptor. Alternatively one can study the field vector itself
which indicates the force on a proton placed at r. The MEF of a receptor may
indicate the route by which a ligand is guided towards the binding pocket. Being
a vector quantity the field is rather more difficult to visualize than the electrostatic
potential and electron density, and hence it has probably been less used in drug
design studies. However, it is possible to visualize the electric field, either by
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displaying the vector orientations at points on a regular lattice or by plotting field
lines which indicate the motion of a freely translating proton in the region of the
molecule. The MEF has also been used in quantitative studies of molecular
similarity (Hodgkin & Richards, 1987).
3. DRUG DESIGN BASED ON RECEPTOR STRUCTURE
If the three dimensional structure of a drug target receptor is known the design
problem is substantially different from that based on lead compounds. In this case
direct methods can be used to estimate differences in binding free energy for
different compounds as opposed to the use of purely empirical correlations. The
design process itself is, therefore, often referred to as being de novo. The primary
concern in de novo drug design is computational efficiency. The increased
accuracy of predictions based on higher level theory must be offset against a
smaller range of compounds that can be investigated for the same cost. The choice
of method is also governed by the quality of the structural data and which degrees
of freedom in the system can be safely neglected.
In cases where the structure of a biological target is known, e.g. the crystal
structure of an enzyme critical to viral reproduction, but few or no potential
inhibitors exist, one is faced both with the problem of determining where an active
molecule may bind and proposing potential agonists or antagonists. In such a case
it is common to fix the conformation of the receptor. This neglects the dynamics
of the receptor and implicitly assumes that entropic or enthalpic changes
associated with the accommodation of the receptor to a specific ligand are
negligible. Although this is a big approximation and may result in significant
artifacts from a computational perspective, it is frequently the only option that
yields a tractable starting point for further investigations.
3.1 Site identification
Before an agonist or antagonist can be proposed potential binding sites must be
identified. Although these often can be inferred from mutation studies or by
inspection of the structure for cavities within the molecule or clefts lying on the
surface, in large systems containing many such sites it can be difficult to
definitively identify by inspection for example the enzymically active site.
Calculation and visualization of the electrostatic potential and electric field, as
described previously in regard to empirical approaches, can be used to aid this
process. As the host molecule consists very often of many thousands of atoms, one
usually assigns point charges to atoms and calculates the various properties
classically. The molecular electrostatic potential (MEP) can indicate regions
where positive or negative charge will bind favourably. The MEP of the active site
is expected to be complementary to that of ligands which bind - this is one
criterion for identification of the site. The MEF can indicate the force on a charge
and thus the vector field can be particularly instructive in showing how a charged
ligand is directed towards the binding site, thus helping to identify the site.
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One step beyond a simple electrostatic view of the host molecule is to
incorporate other force-field terms to represent additional intermolecular forces.
A widely used and conceptually appealing method is that of Goodford and co-
workers called GRID (Goodford, 1985). The interaction of a probe, e.g. a
functional group typically found on a ligand, such as methyl (-CH3), amino
(-NH2), carbonyl (= O), and hydroxy (-OH), or a water molecule, is calculated with
the fixed macromolecule. The energy of interaction of the probe is calculated at
the points of a three dimensional grid superimposed over the macromolecule using
an empirical potential energy function. The resulting energy values are contoured
in three dimensions and displayed graphically along with the macromolecule.
Contours at negative energy are assumed to indicate attractive regions for the
probe and should occur in the binding pocket for probes found on known ligands.
The most negative regions indicate the most favourable binding locations. The
potential energy function used by GRID consists of three terms: (i) a van der
Waals 6—12 function, which can be considered as defining the shape of the probe,
(ii) an electrostatic interaction, which is a Coulombic potential containing a
distance-dependent dielectric permittivity related to the environment of the
interacting atoms, and (iii) a hydrogen bonding term which is angle dependent and
allows for some mobility of the hydrogen atoms and lone-pairs (Boobbyer et al.
1989; Wade et al. 1993; Wade & Goodford, 1993). There are a number of
simplifications present in this approach, which also occur in some other force field
methods. Entropy is totally neglected, pairwise additivity of terms is assumed, no
polarization or redistribution of charge is permitted and the macromolecule is
treated as a static entity. The method is widely used because the information that
results is simple to visualize and straightforward to interpret. The most negative
contour regions show where most favourable enthalpic binding of a functional
group will occur. Contours at less negative values indicate the amount of
movement a probe may undergo and still have favourable interactions. The
closeness of the contours can indicate what forces the probe would be under and
in what direction these act. Together these factors often allow one to identify a
binding site and further help in the design of potential ligands that will bind to the
site.
3.2 Shape based docking
The DOCK algorithm (Kuntz et al. 1982; Desjarlais et al. 1986; Shoichet et al.
1992) attempts to generate geometrically feasible alignments of ligands within a
receptor site of known structure based on a detailed matching of molecular
surfaces. The volume of the binding site and that of potential ligands are first
represented as a series of spheres which fit into their respective solvent accessible
surfaces (Connolly, 1983). The ligands are treated either as completely rigid or as
a series of rigid sub-fragments. Inter-sphere distances are then scanned for
matches within a given tolerance and the structures superimposed based on
matched distances. This generates a large number of potential alignments that are
ranked in accordance to a given scoring function. The default scoring function has
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varied in each implementation. In the most recent implementation a lattice is
placed covering the receptor site and scores are accumulated for each lattice point
that lies within a given cutoff distance of a ligand atom (Shoichet et al. 1992).
Large negative scores are recorded for atoms which overlap with the lattice points.
Different cutoff distances can be chosen for different atom types to account for
close contacts of atoms involved in hydrogen bonding. Other scoring functions
including a mixture of hard sphere and hydrogen bonding terms, a continuous
scoring function based on inter-atom distances or interaction energies based on
the AMBER force field have been used with mixed success.
Shape complementarity algorithms such as DOCK discriminate on a detailed
matching of molecular surfaces. Using conformations of the receptor and ligand
derived from crystallographic studies of the complex such algorithms routinely
reproduce the experimental structure. However, such methods are sensitive to
changes in the geometry of either the ligand or the receptor. Using DOCK to scan
a data base for possible inhibitors of thymidylate synthase 3 of the 25 best scoring
compounds inhibited the enzyme at sub millimolar concentrations.
Crystallographic studies of one of the resulting complexes revealed that the bound
inhibitor was shifted by o-6-o-9 nm, binding to a different region of the active site
(Shoichet et al. 1993). In a more recent study on non-peptide inhibitors of HIV-
protease a proposed inhibitor bound 048 nm away and rotated by 790 from the
predicted location in a different conformation than the docked structure
(Rutenber et al. 1993). In that these and other investigations have led to novel
inhibitors in different systems the method has been an undoubtable success. In
regard to the prediction of the location of the binding site, the orientation of the
ligand within a given site, or specific hydrogen bonding contacts, purposes for
which the method was designed, the results are so far discouraging.
3.3 Fragment build-up
An alternative to molecular docking algorithms are fragment build-up procedures
in which potential ligand molecules are constructed from simple precursors. Such
schemes have the advantage that completely novel compounds can be suggested.
However, as with docking algorithms such as DOCK, the accuracy of these
methods is determined primarily by the form of the scoring function or force field
calculation that must be used to discriminate between potential ligands and
binding modes. Because the methods generate a very large number of alternatives,
the discriminating function is in general crude and factors such as potential
flexibility in the receptor site are not considered.
The types of compounds that will be suggested and the sophistication of the
discriminating functions that can be used depend to a large degree on the
implementation of the method. The build-up procedure GROW (Moon & Howe,
1991) constructs peptide models from a user selected starting position by piecing
together amino acid fragments in conformations that will interact most favourably
with surrounding atoms in the proposed receptor site. GROW operates by
sequentially attempting to add all fragments from a preconstructed library to a
given seed. To score each compound an interaction energy between the receptor
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and the test compound is determined based on the AMBER molecular mechanics
force field and a correction term for ligand desolvation. A manageable number of
test compounds is maintained by only propagating the ten lowest energy
conformations each round. The combination of assuming a rigid receptor, fixed
ligand geometries and scoring on the basis of an interaction energy that includes
a highly non-linear 6-12 van der Waals term means that, like DOCK, GROW
discriminates primarily on a detailed matching of molecular surfaces. For this
reason GROW, as expected, faithfully reproduces the sequence and configuration
of peptides co-crystallized with a given receptor. The method is, however,
extremely sensitive to the choice of starting position which must either be selected
by the user or obtained using an algorithm such as DOCK. For this reason
GROW is primarily applicable to the extension of a pre-existing ligand or in
proposing alternate amino acid residues for a pre-existing ligand.
An example of an alternative implementation of a build-up procedure is the
program LUDI (Bohm, 1992 a, b). LUDI aims to position small molecules into
clefts or cavities in a protein structure such that protein hydrogen bond donors or
acceptors and possible hydrophobic contacts are satisfied. This is done by first
defining a series of interaction sites. In the later implementation a rule based
procedure is preferred to define sites, but methods based on hydrogen bond and
hydrophobic distributions extracted from structural databases or a probe atom
procedure such as GRID are also described. Distances between interaction sites
are then used to select and dock molecules from a rigid fragment library. To
generate the final compounds bridging groups are used to join fragments. Again
this procedure will correctly suggest a ligand that has been co-crystallized with a
given receptor but is later deleted from the structure. The advantage of a LUDI
type build-up procedure over DOCK or GROW is that the initial placing of
unbridged fragments is performed independently, and a degree of tolerance in the
positioning of the fragments is inherent in the method. Thus, the method is more
tolerant, but less discriminating on the basis of surface matching. LUDI uses a
rule based scoring function to discriminate between potential ligands based on
hydrogen bond geometries, volume overlap and buried surface area. Such rule
based functions are essentially empirical and necessarily hold only for the range of
compounds against which they are fitted.
Buildup procedures illustrated by GROW and LUDI in general attempt to
grow or join molecular fragments based on known structures. Recently, however,
a number of atom based methods have also been proposed (Nishibata & Itai, 1991;
Rotstein & Murcko, 1993; Pearlman & Murcko, 1993). The most novel of these
methods is that of Pearlman and Murcko, which attempts to dynamically allocate
atom types and bonding topologies during a molecular dynamics simulation of a
number of initially unconnected atoms, the motions of which are restrained to the
volume of a proposed binding site. The atoms interact with the receptor via the
AMBER molecular mechanics force field and Monte Carlo type moves are used
to change atom types and bonded interactions. Although conceptually interesting,
the computational cost of this method probably cannot be justified in terms of its
ability to suggest and discriminate between potential inhibitors. Atom based
build-up procedures can also lead to chemically unreasonable structures.
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A. Model building
B. Energy calculation
• packing considerations
• matching of hydrogen bond
donors and acceptors
• matching of opposite charges
• electric field evaluation
r
- systematic search (SS)
• heuristic search (HS)
• energy minimization (EM)
• Monte Carlo simulation (MC)
• molecular dynamics (MD)
• stochastic dynamics (SD) >
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Fig. i. Different levels of sophistication of molecular modelling.
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FLEXIBLE
FLEXIBLE
ENTROPY
4. DRUG DESIGN BASED ON RECEPTOR-LI GAND INTERACTIONS
When both the spatial structure of receptor and ligand and their relative position
and orientation are approximately known, one may attempt to calculate a binding
constant based on an evaluation of the atomic interactions between receptor and
ligand atoms, both in the bound and unbound states. In such a calculation a
variety of choices is to be made. Which (atomic) interaction sites are included in
the (free) energy calculation ? Which degrees of freedom (atomic, electronic) are
explicitly used as variables in the calculation. For example, is a rigid model or a
flexible model used? To which extent is the environment (solvent, ions,
membrane) taken into account in the calculation, and in which manner, e.g. as a
mean interaction or explicitly? Is only energy calculated or are entropic
contributions to the free energy also included ?
Different levels of sophistication with respect to the modelling of receptor-
ligand interactions are distinguished in Fig. 1. The simplest level is indicated by
the term model building, and involves an evaluation of the binding capacity of
receptor and ligand based on spatial packing considerations, the matching of
hydrogen bond donors and acceptors, of opposite electric charges or on an electric
field evaluation, all using a rigid receptor-ligand structural model. For example,
the electrostatic component of a binding energy may be estimated by calculating
the electric field at the binding site due to charges on the receptor and then
evaluating the energy of the ligand charges in this field. In such a calculation the
precise conformations of receptor and ligand are not expected to play a significant
role, since the electrostatic interaction is a slowly varying function of the distance
between charges. It is the absence or presence of a charge which influences the
field and energy, not its precise location at a distance from the binding site.
However, when considering interactions such as the van der Waals, covalent
bond-length and bond-angle interactions, which possess a much larger sensitivity
to the distance between interaction sites, the interaction energy obtained will be
sensitive to small changes in receptor and ligand structure. In this case the relative
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energies obtained for different rigid receptor-ligand structures are not likely to
correspond to the relative binding energies of the relaxed structures of the
complexes.
The next level of sophistication of molecular modelling (Fig. 1) involves the
incorporation of molecular flexibility as illustrated in Fig. 2. Flexibility can be
taken into account by using an energy function or interaction potential Uphys{r),
which contains general physical information on molecular structure and
flexibility. For example (van Gunsteren & Berendsen, 1990), an interaction
function for biomolecular systems is
bonds n angles n
improperdihedralsn
+ S *£• [1+cos (mB & , -
dihedrals n
< , J / y 4 , 0 e r r < , ) ] . ( 14 )
pairs (i, j)
It describes the energy of a molecular system as a function of the atomic
coordinates of the JVatoms of the system, indicated generally by r. Expression (14)
uses internal coordinates such as bond lengths bn, bond angles 6n, improper
dihedral angles £n and (proper) dihedral or torsional angles <j)n . The last term in
(14) representing the nonbonded interaction is expressed in terms of the distance
rti = [(r{ — Tj) • (rt — r3-)p between atoms i and j . In the numerical practice the
internal coordinates bn, 6n, £n and <pn are also expressed in terms of the cartesian
coordinates (rltr2,... ,rN) = r of the N atoms. The functional form and the
parameters (bon,kbn,Bon,kbna,^n, k%,mn,8n,kf,Bt}^li},qi,eT) = sof Uphyi{r;s) contain the
general physical information on biomolecular systems: ideal bond lengths b°n, the
variation of which is controlled by the size of kbn, partial atomic charges qt , van
der Waals parameters Ay and Btj , etc. They are chosen such that the function
Uphv5(r;s) represents, as well as possible, the energy of a particular type of
molecular system as a function of molecular configuration r.
Molecular modelling using an energy function such as (14) involves three basic
choices.
1. Which degrees of freedom are explicitly treated as variables, e.g. rlt r2, . . . , rN
in Uphys(r;s), and which are implicitly taken into account through the use of an
effective interaction or potential of mean force for the explicit degrees of
freedom ? Such an effective interaction should contain the mean effect of the
degrees of freedom which are not explicitly treated as variables in the molecular
model, but which are averaged or treated as parameters. For example, the
nuclear coordinates are often treated as parameters in a quantum mechanical
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Fig. 2. An overlay of twenty configurations after a best fit superposition of all C atoms
from a loops simulation of porcine insulin in aqueous solution illustrating the range of
configurational space accessible to the protein on a subanosecond time scale.
calculation of molecular properties using (part of) the electronic degrees of
freedom as variables. Or, the parameters (s) of empirical classical interaction
functions such as (14) are generally determined such that the interaction energy
Uphys includes the mean effect of the (omitted) electronic degrees of freedom.
A biomolecular system such as a receptor-ligand complex has in general more
degrees of freedom (electronic, atomic) than can be reasonably treated as
variables. Therefore, one has to select those degrees of freedom as variables in
the molecular model, that are essential to a proper representation of the
quantity or phenomenon one is interested in. With respect to the calculation of
binding constants all degrees of freedom that are expected to give significant
contributions to the energy or entropy of the complex compared to the
individual receptor and ligand molecules, should be explicitly treated.
How is the interaction function for these degrees of freedom denned ? This can
be done at different levels of sophistication. Interaction functions of the
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simplest type that are generally used in crystallographic modelling contain only
terms describing covalent bond lengths, bond angles and chirality centers, and
van der Waals repulsion between atoms. General empirical energy functions
usually also contain terms representing dispersion energy and Coulomb energy
(Gelin, 1993). A higher level of sophistication, without explicitly entering the
realm of quantum mechanics, is reached by the inclusion of terms describing
the electronic polarisability of atoms in the energy function. With respect to the
calculation of binding constants such polarisation terms will be particularly
important when a charged ligand is bound to a receptor. A mean treatment of
electronic polarisation as in (14) may not be sufficient to obtain accurate
binding constants in such a case.
How are the explicitly treated degrees of freedom sampled ? Biomolecular
complexes constitute microscopic systems, the properties of which are
governed by the laws of statistical mechanics. This means that the probability
of occurrence of a molecular (receptor-ligand) configuration r with energy
Uphys{r;s) is proportional to its Boltzmann factor
P(r)ccexp[-Uphys(r;s)/kBT]. (15)
A set of structures or configurations, in which each particular structure r occurs
with relative probability P(r) according to (15) is called a Boltzmann ensemble
or distribution of configurations. The third basic choice of molecular modelling
using energy functions involves the method by which a set of molecular
configurations is generated (Fig. 1). For molecular complexes with a few
explicit degrees of freedom these may be systematically varied (or searched :SS)
to find the configurations with the lowest energy Uphys(r;s), which will have the
highest probability of occurrence P(r). If the number of degrees of freedom
grows, a systematic search of the vast configurational space of the molecular
complex becomes impossible. Then, heuristic search (HS) methods, which
visit a tiny, but hopefully representative set of configurations, are the only
way to sample the Boltzmann ensemble. Though a simple method, energy
minimisation (EM) is a very poor searching and sampling method, since it
produces only one configuration which is a local minimum close to the initial
structure. Much more powerful are methods such as Monte Carlo (MC)
(Frenkel, 1993), molecular dynamics (MD) or stochastic dynamics (SD) (van
Gunsteren, 1993) simulation, or combinations of these, that directly generate
a Boltzmann ensemble. Since each configuration r in such an ensemble occurs
with probability (15), averages and higher moments of the distributions can
directly be calculated over the ensemble using a weight factor 1. A variety of
even more powerful searching and sampling methods are known (van Schaik et
al. 1992, 1993; Scheraga, 1993; Huber et al. 1994), which generally do not
produce a Boltzmann ensemble of configurations. When taking averages of
physical quantities over such a (non-Boltzmann) set of configurations, each
configuration should be given the weight (15) in order to obtain a Boltzmann
average. The calculation of binding constants should always be based on a
Boltzmann average.
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The next level of sophistication of molecular modelling involves the explicit
evaluation of entropy or free energy (Fig. 1). From a Boltzmann ensemble the
statistical equilibrium averages can be obtained for any desired property of the
molecular system for which a value can be computed for each configuration of the
ensemble. Examples of such properties are the potential or kinetic energy of (parts
of) the system, structural properties, electric fields, etc. A number of
thermodynamic properties can be derived from such averages. However, two
important thermodynamic quantities, the entropy and the (Gibbs or Helmholtz)
free energy, generally cannot be calculated using a statistical average. They are
global properties of the molecular system that depend on the extent of
configuration (or phase) space accessible to the system. Therefore, computation of
the absolute free energy of a molecular system is virtually impossible. Yet,
quantities important to drug design, such as binding constants and solubilities, are
directly related to the free energy. Fortunately, over the past decade statistical
mechanical procedures have evolved for evaluating relative free energy
differences. They are rather demanding as far as computing power is concerned,
but are very applicable in drug design based on receptor-ligand interactions.
4.1 Structure and energy calculations using flexible jD-structure-based models
Molecular modelling of receptor-ligand complexes based on the matching of
receptor and ligand properties or using rigid 3D-structures of receptor and ligand
will produce a first estimate of the binding constant. Whether such an estimate
bears any relation to reality will depend on the characteristics of the molecular
system. For the binding of a rigid, positively charged receptor to a relatively rigid,
negatively charged receptor (protein) it may be a reasonable estimate. However,
for highly flexible molecules such as antibodies and antigens such an estimate is
likely to be useless. In such cases flexibility of receptor, ligand and solvent has to
be accounted for. Fig. 2 gives an impression of the flexibility of the protein insulin.
4.1.1 Flexibility of ligand and receptor
By using an energy function such as (14) for the atoms of the receptor and ligand,
molecular flexibility can be accounted for in the drug design procedure. However,
it depends on the technique used to search and sample molecular configurations,
whether the potential molecular flexibility inherent to the energy function will be
reflected in the energies and structures of the receptor-ligand complex that are
obtained. The most commonly used search and sampling techniques are energy
minimization, which only relaxes local strain in a molecular structure, and MC or
MD simulation combined with high temperature annealing to extend the search
(Goodsell & Olson, 1990; Kuntz, 1992; Stoddard & Koshland, 1992; Hodgkin et
al. 1993).
Although the introduction of flexibility will in general improve the molecular
model, it will only do so if the assumption of molecular rigidity is the accuracy
limiting factor. If this is not the case the use of e.g. MC sampling techniques to
sample conformations of flexible protein sidechains will not produce better
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agreement with experimental data than simple modelling based on geometrical
properties of amino acid sidechains (van Gunsteren & Mark, 19926).
4.1.2 Solvent effects
An obvious way to limit the number of explicitly treated degrees of freedom in a
biomolecular system is to omit all or almost .all solvent degrees of freedom. Due
to the abundance of solvent degrees of freedom for a biomolecule in solution,
omission of these in an energy calculation easily reduces the required computing
power by a factor of 10 to 50. Therefore, most drug design studies are carried out
for molecules in vacua. The complete neglect of solvent effects will limit the
accuracy of the calculated properties, such as binding constants. So, what is the
role of solvent molecules in a biomolecular system ? The structure and stability of
a molecular complex may depend on the type of solvent. Individual water
molecules may play a structural role in e.g. protein-ligand or inhibitor binding.
Polar solvents exert a dielectric screening effect on interactions between charges
on the receptor and ligand, and the viscosity of the solvent will influence the
dynamics of the atoms of the molecular complex, and may also influence the
kinetics of the binding process.
Due to the many different low energy configurations occurring in a liquid, a
solvent cannot be characterized by one or a few molecular configurations, but a
(Boltzmann) ensemble of solvent configurations should be generated. So, when
solvent degrees of freedom are included in the energy function (14), simulation
techniques such as MC or MD are to be used, and systematic search (SS) and
energy minimization (EM) are useless.
When simulating a microscopic system of finite size, the boundary of the system
should be treated such as to minimize edge effects. The standard procedure is to
use periodic boundary conditions. The solute or molecular complex and the
surrounding solvent molecules are put into a periodic space-filling box, which is
treated as if it is surrounded by identical translated images of itself. In this way
basically an infinite periodic system is simulated. The periodic box should be
taken large enough to avoid interactions between molecules and their periodic
images, as illustrated in Fig. 3. This condition leads to sizeable amounts of solvent
molecules, typically a few hundreds to thousands, to solvate the receptor, ligand
or the complex, which makes such simulations expensive (van Gunsteren & Mark,
1992a).
An alternative to the explicit treatment of solvent molecules in a biomolecular
simulation is an implicit one: the influence of the solvent on the solute degrees of
freedom is incorporated in the energy function of the latter in an average manner.
A potential of mean (solvent) force is used for the solute. Different mean solvation
models are in use (van Gunsteren et al. 19946).
1. Accessible surface area type models
In this type of mean solvation model the local solvent contribution to the
potential of mean force for solute atoms is taken to be proportional to the area
of the solute atom or group of atoms that is accessible to solvent molecules (Ooi
et al. 1987; Still et al. 1990; Schiffer et al. 1992; Wesson & Eisenberg, 1992).
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Fig. 3. The central or parent simulation cell from a simulation of hen egg white lysozyme
(green) solvated by 5300 SPC water molecules with spherical (truncated octahedron)
periodic boundary conditions illustrating the amount of solvent required to approximate
infinite dilution in a periodic system.
Other local quantities, such as the hydration volume (Kang et al. 1988; Vila et
al. 1991), or the number of solute-solvent contacts (Stouten et al. 1993) can be
used too. The expression for the accessible surface area of a solute atom
generally depends on the coordinates of the solute atom itself and those of its
nearest neighbour solute atoms. Thus, a mean force potential based on an
accessible area model becomes a many-body interaction which generally
involves non-negligible computational effort. Currently, it is not clear whether
this increased effort is offset by the limited accuracy of such mean solvation
models in mimicking solvent effects.
2. Simple pairwise solvation force models
The computation of the mean force of solvation would be considerably
simplified and sped up, if the mean force could be formulated as a sum of
pairwise (two-body) interactions. In fact, the mean force potential in the
solvent contact or occupancy model (Stouten et al. 1993) can be expressed as
a sum of two-body terms of the form expi — r^/za2), where rtj is the distance
between particles i andj. A slightly different functional form has been proposed
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by van Gunsteren et al. (1994^). Although the use of a simple pairwise
solvation force induces only a minor increase of the required computing effort,
it remains to be investigated whether its accuracy is comparable to that of a
simulation including a (thick) layer of solvent molecules.
3. Dielectric screening models
Different approximate models for treating the long-range solute-solvent
interactions due to dielectric screening and polarization effects are available too
(Still et al. 1990; Solmajer & Mehler, 1991; Sharp, 1991, 1993; Gilson &
Honig, 1991). Still et al. (1990) use an expression involving only one-body and
two-body terms, which is based on the continuum approximation of a dielectric
medium. A simple approach is to make the relative dielectric permittivity, e,
distance dependent, for example using a linear (Pickersgill, 1988) or sigmoidal
function (Solmajer & Mehler, 1991) of the atom-atom distance. A more
complicated way to incorporate long-range electrostatic effects using a
continuum representation of the solvent is based on solving the Poisson-
Boltzmann equation on a 3-dimensional grid (Sharp, 1991), from which a
simple two-body interaction term is derived that accounts for charge-solvent
interactions in an average way (Gilson & Honig, 1991). For reviews on the
treatment of long-range electrostatic interactions in molecular simulations we
refer to (Sharp, 1993; Berendsen, 1993; Smith & van Gunsteren, 1993).
Generally, the structure and stability of a molecular complex in aqueous
solution will depend on the ionic strength of the solution. This implies that the
presence of ions in the solvent should either be explicitly simulated (de Vlieg et al.
1989) or accounted for in an average manner by e.g. a Poisson-Boltzmann
continuum model (Smith & van Gunsteren, 1993). Although the long-ranged
interactions between ions in aqueous solution can be adequately approximated in
a simulation, the explicit inclusion of ions in a simulation of a receptor-ligand
complex in aqueous solution may not yield reliable results, since the relaxation
time of a ionic distribution is likely to be longer than the simulation period. This
slow relaxation is caused by the slow diffusion of hydrated ions in solution. In a
biomolecular simulation including water and counterions, the simulation averages
may then be easily based on non-equilibrated ion distributions, causing sizeable
deviations from the mean effect of the ions. Therefore, the mean influence of the
ionic solution might be better approximated by a simulation which only includes
solvating water molecules.
4.1.3 Incorporation of experimental data in a simulation
If the molecular model and energy function Uphys(r;s) are perfect and if a
simulation can be carried on for an infinitely long time, the generated ensemble of
molecular configurations will exactly represent the real molecular system: the
structural and energetic properties derived from such an ensemble will be correct.
In practice, neither condition is fulfilled. Atomic interaction functions, such as
(14), are not infinitely accurate due to various approximations with respect to
electronic degrees of freedom, quantum mechanical effects, many-body
interactions, etc. that are made in their derivation. Second, an MD or MC
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computer simulation cannot be carried out for infinitely many steps; typically for
about io6 steps, which is in many cases not enough to sample all relevant
molecular configurations of low energy.
One way to improve the reliability of a molecular simulation is to incorporate
in the simulation experimental information on the particular molecular system
that is simulated (van Gunsteren et al. 1994 a). This can be done by adding to the
standard physical energy function Uphy8(r;s) an extra term Urestr{r;s) which
restrains or influences the motion of the system such that the generated trajectory
or ensemble yields average properties in accordance with the experimental
information on the specific molecular system. Thus, the energy function of the
molecular system becomes
U{r; s) = Upnys(r; s) + UrestT(r ;s). ( !6)
The form of the restraining potential or penalty function Urestr(r ;s) depends on
the type of experimental information, and should be chosen such that its value
increases the more the property, calculated as an average over the trajectory or
ensemble, deviates from the experimental value. Generally, a simple quadratic
function of the difference between the simulated average and the measured value
of a property is used for UTestT(r;s).
For example, a penalty function which restrains the amplitudes of the averaged
structure factors, | < Fcale(hkl) > |, to the observed ones, \Fobs(hkl)\, from an
X-ray diffraction experiment is (Gros et al. 1990)
Urestr(r;k*»,ksc,Fobs) = \k°» S [\Fobs(hkl)\-kJ(Fcalc(hk[)y\f. (17)
reflections hkl
The summation runs over the reciprocal lattice vectors, the symbol < . . . )
denotes a trajectory or ensemble average, ksc is a scaling factor to match the units
of Fcalc and Fobs and k'fr in the force constant that determines the weight of the
term Urestr with respect to the term Uphys in (16).
Other examples of restraining potential energy functions Urestr are found in the
literature concerning structure determination based on NMR data. Nuclear
Overhauser Effect (NOE) intensities can be converted to a set of upper bounds
{ry6} to the distances between atoms (hydrogens) 1 and j , which leads to a so-
called distance restraining function (Kaptein et al. 1985).
Urestr(r;kdr,r-b) =\k« £ [MAX(o, <ry3>-1/3-r«6)]2, (18)
NOE pairs {i,j)
where the function MAX delivers the largest of its two arguments. Similarly, J-
coupling constant values can be restrained to the observed ones J°bs by the
restraining function (Torda el al. 1993)
torsional
angles $(
)>-jn2. (19)
The ^-coupling constant is dependent on the torsional angle involving the three
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covalent bonds connecting the atoms for which the J-value is measured. Also
chemical shifts <r can be restrained to the observed ones o-obs, e.g. by the
restraining function (Harvey & van Gunsteren, 1993)
UrMr(r;k'",o*bt)=\hr S Nr)>-<r*T (20)
resonances i
where the summation runs over the resonances i. An example of the incorporation
of microwave spectroscopic information is found in (King et al. 1993).
The average < ... > in (17-20) can be taken as a time (trajectory)-average (Torda
et al. 1989) or as an average over space, i.e. different molecules (Scheek et al.
1991). In MD or SD simulations the use in (17-20) of the time average
='-£Q(r(t'))dt' (21)
of a quantity Q(r(t')) that^  depends on the molecular coordinates r, is the natural
choice. Formula (21) is the true average of Q and is used in the analysis of MD
or SD trajectories, but it is not suitable for deriving a (restraining) force during
the finite time of a simulation. As time increases, and Q(r(t)) is calculated over a
longer period, the average (21) becomes less sensitive to instantaneous
fluctuations. This problem can be avoided by building a decay into the summation
over time with a characteristic decay time, T, SO that
<Q> = Q(t; r) = [r( 1 - exp ( - 1/T))]"1 f exp ( -1'/r) Q(r(t-1')) dt' (22)
Jo
is used in (17—20) for the ensemble average in Urestr.
The ensemble average in (17—20) could also be implemented as an average over
space, that is, over M different molecules
M / M
<0> = <0>M = 2 e-EW*TQ(rJ S e-*"-"*«J', (23)
m - l / m—1
where the summation runs over equivalent molecules or systems which have a
configuration denoted by rm. This expression assumes that the configurations of
the M molecules are uniformly distributed. The advantage of time averaging over
space averaging is that the relative Boltzmann probability of the configurations of
a trajectory is guaranteed when proper equations of motion are integrated.
Finally, we note that the procedure to incorporate experimental information in
an average manner, as sketched here, can be applied to other than the molecular
properties discussed here. It could be used to force a receptor-ligand complex to
adopt on average a given set of properties.
4.2 Free energy calculations using flexible, ^ D-structure-based models
In terms of the energy, E, and the entropy, 5, the Helmholtz free energy, F, of a
system of N particles in a volume V at a temperature T is given by
F(N, V, T) = E{N, V, T)-TS{N, V, T). (24)
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In terms of the canonical partition function, Z(N,V,T), it is given by
F(N, V, T) = -kB TlnZ(N, V, T)
= -kBTln\(h3NN\yi |Te-"O')/fc*Td*>drl (25)
where kB is Boltzmann's constant, h is Planck's constant and the Hamiltonian,
H(p,r)=Ilp*/(2mi)+U(r), (26)
i-i
expresses the total energy of the system in terms of the coordinates r = (r1>r2,...
,rN), and the conjugate momenta, p = (Pltr2,... ,/>N) of the N particles of the
system. The masses of the particles are indicated by mt and their interaction
function by U{r). From expression (25) it can be readily appreciated that the free
energy is a global property given by a double integral of the (positive) Boltzmann
factor exp[—H(p,r)/kBT] over all possible values of p and r which define the
volume of phase space accessible to the system. Since MD or MC simulations of
large molecular systems necessarily sample only a limited set of configurations,
calculation of the free energy via (25) using a set of MD or MC configurations will
suffer in a systematic way (F being too large) from incomplete sampling of phase
space. Each additional part of phase space that is included in the integral will give
a negative contribution to the free energy and a positive contribution to the
entropy, since the natural logarithm is a monotonically increasing function of its
argument. Even if the simulated configurations are representative of the complete
ensemble and thus reasonably accurate ensemble averages may be calculated, the
integral in (25) will not be accurate.
Re-expressing the free energy as a function of an ensemble average shows the
problem of the practical calculation of free energy in a different manner.
Integrating over the momenta p in the partition function and using jdr = VN, we
find
F(N,V,T) = -kBTln J -
e+U(r)/kB T Q-U(r)/kB T j r
-kB T\n{[2nmkB T/h2fNI2/N\}
= +kB Tln<e+u»">T)NiViT-kB T\n{VN[2nmkB T/h^/Nl} (27)
where the ensemble average <Q> of a microscopically defined quantity Q(J>,r) is
defined by
\Q/N,V,T — rr
sr
= jJ0(P,r)P(p,r)ipir, (28)
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where P(p,r) is the probability of finding the system in the state characterized by
p and r. In an analogous manner the entropy, 5, and the energy, E, can be
expressed in terms of ensemble averages as
S(N, V, T) = - | ^
+ kB\n{VN[znmkBT/h2]3N/2/N\} (29)
and
,V,T. (30)
Accurate calculation of the free energy and entropy is not possible due to the
occurrence of the ensemble average <exp[+ U/kBT\y in (27) and (29). Since the
probability P(r) of a molecular configuration is proportional to the Boltzmann
factor exp[— U(r)/kBT\, it is small when the function to be averaged,
exp[ + U(r)/kBT], is large and vice versa. For other quantities, e.g. the energy E,
this problem does not occur when evaluating the ensemble average in (30).
In view of these difficulties, the calculation of the absolute free energy or
entropy of a molecular system is virtually impossible. However, over the last
decade statistical mechanical procedures to evaluate relative free energies have
evolved, which are applicable to molecular systems of biochemical interest. For
reviews of these techniques we refer to (Beveridge & DiCapua, 1989; King, 1993 ;
van Gunsteren et al. 1993; Straatsma et al. 1993).
4.2.1 Free energy differences by thermodynamic integration
Using the so-called coupling parameter approach the difference in free energy
between two states A and B of a system can be determined, if the Hamiltonian of
the system is made a function of a coupling parameter A, thus H{p,r;X), such that
when A = A^  the system corresponds to state A, H(p,r;XA) = HA(p,r), and when
A = AB, the system corresponds to state B, H(p,r;XB) — HB(p,r). The partition
function
Z(N, V, T; A) = (/z^N!)-1 jTe""^'^/**21 dpdr (31)
becomes a function of A, and so does the free energy
,T;A) = -kBT\nZ(N,V,T;A). (32)
The difference in free energy between the two states A and B becomes (for the
same N, V, and T)
AFBA = F(\B)-F(XA)= fV(A)dA (33)
JA.4
where -F'(A) = dF/dX. To simplify the notation, we drop the indication of constant
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N, Fand Tfor the remainder of the discussion. Differentiating (32) with respect
to A we find
where the probability of occurrence of molecular configuration (and momenta)
P(P,r;A) and the ensemble average < ... >A defined in (28) have become dependent
on A. The advantage of formulae (33-34) over (25), (27) and (29) is clear: a relative
free energy can be computed as an integral over the ensemble average of the
derivative of the Hamiltonian with respect to the coupling parameter A. This
ensemble average does not suffer from the sampling problem which prohibits the
computation of the absolute free energy via (25) or (27). Formulae (33-34) are
called the thermodynamic integration formulae, which name originates in the
analogy with obtaining free energy differences between states with different
temperature or volume in thermodynamics.
The. practical use of (33—34) involves three important issues.
1. The choice of the A-dependence of H(p,r;X), which defines the pathway from
state A to state B. Since the free energy is a state function, the change in free
energy will in principle be independent of the path chosen. However, in
practice this choice strongly influences the accuracy of the free energy
difference obtained and the computational efficiency. The pathway should be
chosen such that the relaxation time of the system with respect to the change
in Hamiltonian and the time required to sample the ensemble are both
minimized. This implies that the most direct path is not necessarily the most
efficient (Mark et al. 1991). For a more elaborate discussion of the rather
technical, but important considerations concerning the choice of H{p,r\X) we
refer to the literature (van Gunsteren et al. 1993; Beutler et al. 1994; Mark &
van Gunsteren, 19946).
2. Determination of the ensemble averages <. . . )A via computer simulation, in
which proper equilibration and sampling are essential ingredients. At each A-
value the ensemble average <...>A should be well converged and should
include the molecular configurations that belong to the substate of the system
which is defined by the particular value of A. If A changes, the range of these
configurations may change and so will the entropy of the system. The range of
configurations that can contribute to the ensemble average in a specific case is
illustrated in Figures 4A and B. In practice, a primary if not the major source
Fig. 4. An illustration of the range of configurational states that make up the ensemble of
accessible states that must be sampled to reliably estimate the derivative of free energy at a
specific value A. The figure shows an overlay of four randomly selected configurations from
a loops simulation of a complex of benzamidine with human thrombin. Fluctuations of the
protein backbone are shown in A. Motion of the bound ligand is shown in B.
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of error in free energy calculations is failure to sample a representative
ensemble (Berendsen, 1991; Mark et al. 1994).
3. Evaluation of the integral over A in (33). This is preferably done by computing
the integrand (ensemble averages) at a few fixed A-values and using simple
numerical integration methods such as the trapezoidal rule, Simpson's rule or
cubic spline integration (Mark et al. 1994).
4.2.2 Thermodynamic cycles
The next step when using the thermodynamic integration technique to calculate
relative free energies, or binding constants of receptor-ligand complexes, or
solubilities, is to formulate a so-called thermodynamic cycle (Beveridge &
DiCapua, 1989). The basis on which the thermodynamic cycle approach rests is
the fact that the free energy F is a thermodynamic state function. This means that
as long as a system in equilibrium is changed in a reversible way, the change in free
energy AF will be independent of the path of change. Therefore, along a closed
path or cycle one has AF = o. This result implies that there are two possibilities
of obtaining AF for a specific process. One may calculate it directly using the
techniques discussed above along a path corresponding to the process, or one may
design a cycle of which the specific process is only a part and calculate the AF of
the remaining part of the cycle. The power of this thermodynamic cycle technique
lies in the fact that on a computer also non-chemical processes such as the
conversion of one type of atom into another type may be performed.
In order to visualize the method, we consider the relative binding of two
inhibitors IA and IB to an enzyme E. The appropriate thermodynamic cycle for
obtaining the relative binding constant is
l(exp.)
3(sim.) Usim.) (35)
where the symbol : means complex formation. The relative binding constant
equals
KJK, = expi-iAFt-AFJ/RT] (36)
where R denotes the gas constant. However, simulation of processes 1 and 2 is
virtually impossible, since it would involve the removal of many solvent molecules
from the binding site of the inhibitor on the enzyme to be substituted by the
inhibitor in a reversible manner. But, since (35) is a cycle we have
AF^AFx = AFi-AF3 (37)
and, if the composition of inhibitor IB is not too different from that of IA, the
desired result can be obtained by simulating the non-chemical processes 3 and 4
in a reversible manner.
Not every thermodynamic cycle one can think of can be used to obtain a relative
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free energy difference by simulation using the method of thermodynamic
integration (Shi et al. 1993). For example, the problem of protein stability can be
described using the cycle (Dang et al. 1989; Tidor & Karplus, 1991)
l(exp.)
NF — - > Nn
3(sim.)
> M
4(sim.?) (38)
where the folded (F) or denatured (£)) form of a native (N) protein or a mutant
(M) are the four systems involved. As before, the denaturation processes 1 and 2
cannot be carried out reversibly on a computer. If the mutation is not too large,
process 3 may be carried out reversibly by simulation, but process 4 poses
insurmountable problems: we do not know much about the denatured state of a
protein, but the equilibration time and the sampling time of a partially unfolded
protein certainly lie far beyond current computational limits. A similar situation
is encountered when considering a thermodynamic cycle involving antibody-
antigen binding. T h e equilibration and sampling of unbound linear peptides of
sizeable length in aqueous solution still lies outside current computational
possibilities.
4.2.3 Use of restraints or constraints in a free energy calculation
Since computer simulation of biomolecular complexes is still computationally
expensive, one may try to reduce the extent of configuration space that is to be
sampled by restraining the motion along part of the degrees of freedom of the
system using a so-called restraining potential energy term, which is added to the
Hamiltonian of the system. For example, spectroscopic data obtained by NMR
measurements, such as Nuclear Overhauser Enhancement (NOE) intensities, J-
coupling constants and chemical shifts may be used in such a restraining energy
function term to generate an ensemble of protein structures that satisfies these
experimental data (Kaptein et al. 1985; Torda et al. 1990, 1993; Harvey & van
Gunsteren, 1993). In protein crystallography similar restraining terms involving
measured structure factor amplitudes have been used for the same purpose
(Briinger et al. 1987; Gros et al. 1990). Another example is the often used
technique of restraining the motion of atoms that lie near the boundary of the
system that is simulated in order to counteract the distortive forces due to the non-
physical boundary and the vacuum beyond it. The atoms in the extended wall
region are e.g. harmonically restrained to stationary positions (Brooks et al. 1985)
or can be kept fixed (Berkowitz & McCammon, 1982). In the latter case one would
rather speak of constraints than restraints. Constraints are also generally used to
maintain fixed bond lengths or bond angles in a simulation to allow for larger
integration time steps (van Gunsteren & Berendsen, 1990).
When restraints or constraints are used, the Hamiltonian of the system is
different from the unrestrained or unconstrained one, which generally leads to a
different ensemble being generated, and hence generally to different free energy
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estimates. The introduction of constraints leads to metric tensor corrections (van
Gunsteren et al. 1993). When applying bond length constraints, the correction is
generally small and can be safely ignored. However, when a constrained bond
length is changed as a function of A in the coupling parameter approach, this
change will contribute to the free energy change, irrespective of the method used
to generate the ensemble or to maintain the constraint (Straatsma et al. 1992; van
Gunsteren et al. 1993). The derivative of the (constrained) Hamiltonian with
respect to the changing bond length must be determined and averaged over the
ensemble. In other words, the force exerted by the environment to change the
constraint, which is resisted by the constraint, must be determined and averaged.
This force yields a contribution to the free energy: work done by the constraint
force when changing the constraints. So, the contribution of a changing constraint
(or restraint) to a free energy change can generally not be neglected. The amount
of work done by the constraint (or restraint) forces will depend on the
environment of the atoms involved in the changing constraint (or restraint). A
growing bond length or bond angle may encounter a different resistance inside the
protein than in solvent, so the amount of work done may be different. This implies
that one generally cannot invoke cancellation of contributions from constraint (or
restraint) forces to a free energy change computed along parallel legs of a
thermodynamic cycle, e.g. processes 3 and 4 in (35), unless the environments of
the changing constraint (or restraint) are very similar along both legs 3 and 4 of
the cycle. The latter condition is in principle not fulfilled, since the basic idea of
using a thermodynamic cycle is to compute the difference in free energy change
of two different processes.
If the constraint or restraint term in the Hamiltonian does not depend on the
coupling parameter A, it will not yield a direct contribution to the free energy
change, since its derivative with respect to A equals zero. However, such A-
independent restraining may still strongly affect the free energy estimate obtained
due to the restriction of the accessible configuration space of the system. For
example, when applying position restraining to atoms in the extended wall region
of the system, or when using instantaneous distance restraints based on NMR
data, the motions of the atoms involved in these restraints are severely restricted,
which restricts the ensemble of structures contributing to the energy and entropy.
In such cases, the free energy estimate obtained is correct in terms of statistical
mechanics, but not representative of the real molecular system involving the full
atomic motions.
Summarizing we conclude that the application of constraints or restraints in
simulations to obtain free energy estimates must be carefully considered both with
respect to their direct contributions to free energy changes and with respect to
their implications to a proper sampling of the configurations of the system that are
relevant to the change in (free) energy and entropy that one aims to determine.
4.2.4 Reliability and test of computed free energy differences
When performing free energy calculations in practice, one would like to obtain an
impression of the reliability of the obtained free energy differences. Below we list
a number of possibilities to this end.
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When computing ensemble averages < ... >A, such as in (34) from a molecular
simulation, the convergence of the ensemble average as a function of the
number of simulation steps or time should be monitored at each chosen A-
value. If the simulation covers only a few picoseconds, only the fastest (bond,
bond-angle) vibrations are sampled, and therefore reliably contribute to the
free energy estimate, and other motions are neither equilibrated nor sufficiently
sampled.
The addition of extra A-values in the numerical integration over A in (33)
should not dramatically change the AFBA value obtained so far. When creating
or deleting atoms as a function of A, accurate integration near the boundaries
of the interval [A ,^,AB] may require extra integration points (Mark et al. 1994).
When carrying out more than one change of a system, e.g. from inhibitor A to
B and from inhibitor A to C, the quality of the equilibration, sampling and
integration over A can be tested by performing the change from inhibitor B to
C, which closes a cycle:
+ AFCB + AFAC = o. (39)
4. Repetition of individual simulations with different initial (equilibrium)
configurations or velocities should yield the same result.
5. Small changes in the computational procedure should not affect the AFBA value
obtained (Shi et al. 1993).
We note that agreement with experimentally obtained free energy differences is
a necessary, but not a sufficient condition for having obtained a reliable theoretical
free energy estimate. In general, one is comparing a few numbers {AAF values)
calculated for a multi-dimensional system using many assumptions,
approximations and parameters. One might well obtain good agreement between
calculated and measured numbers for the wrong reasons, viz., accidental
agreement, compensation of errors or adjustment of parameters (van Gunsteren,
1990).
Even in the case that entropic effects play no role in the differential binding of
two ligands A and B to a receptor, use of the thermodynamic integration
technique combined with a thermodynamic cycle will yield a more accurate
estimate of the difference in binding energy than just taking the double difference
of the average energies of the bound and unbound systems. In the latter case very
large energies for slightly different systems are subtracted (twice) to obtain much
smaller energy differences. The latter can be easily three orders of magnitude
smaller than the system energies themselves (Fraternali & van Gunsteren, 1994),
which leads to a dramatic loss of accuracy. Since the integrand (34) in the
thermodynamic integration formulae (34-35) contains a derivative of the
Hamiltonian with respect to the coupling parameter A, only interactions that are
chosen to be A-dependent, will contibute to the (free) energy difference, which is,
therefore, in general also orders of magnitude smaller than the system energy.
Subtraction of large system energies can also be partly avoided by using the
difference of the receptor-ligand energies for two different ligands as an estimate
for the relative binding energy. However, such an estimate neglects the possible
changes in intra-receptor and intra-ligand energies upon binding, apart from the
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entropic contributions. So, even if entropic effects play no role in the binding, use
of thermodynamic integration techniques is a most efficient way to obtain relative
binding energy estimates for drug-receptor complexes.
Central to any rational design process is the ability to predict the effect of a
proposed modification on the properties of interest. In the case of drug design the
properties of interest depend directly on the associated changes in free energy.
The basic methodology to predict changes in free energy based on molecular
simulation techniques is well established and potentially highly accurate. Despite
this, the quality of published free energy calculations varies greatly. Reliable free
energy estimates from such calculations can only be obtained if the basic
assumptions of equilibrium and proper sampling, on which the methods are
based, are met.
4.2.5 Free energy decomposition
In the process of drug design it would be of great utility if a free energy of
receptor-ligand binding could be decomposed in terms of contributions of
particular (groups of) ligand atoms or specific types of interactions.
Unfortunately, a meaningful separation of the free energy into specific
components is, in general, not possible. The total free energy of a system can only
be expressed in terms of a sum of components in so far as the total system can be
separated into a set of independent subsystems. This is a direct consequence of the
basic statistical mechanical definitions of free energy and entropy, (27-29) (van
Gunsteren et al. 1993; Mark & van Gunsteren, 1994 a).
A minimum requirement to express the total free energy as a sum of
components is that the Hamiltonian of the system can be expressed as a sum of
components, e.g.
H^H. + H, (40)
where, for example, Hl = Hbond and H2 = Hrest, or H^ = HTesidu<! and H2 = Hresl.
Using (30), we see that the energy of the system can in principle be separated into
components
E=(H} = (H. + H,) = (Hl) + (H^ = El + E2. (41)
The same is not true for either the free energy or the entropy. Combining (27) and
(40) we obtain, apart from a constant term,
F= +*B Tln<e+';/*«T> = +kB rin<e+tV*«7V{/>/*«T>- (42)
This expression can only be factorized to give
F = +klt Tin <e+"'/*«r> <e+';*/*«r>
= klt Tin <e+"i'*«T> + ku Tin (e+'J*/lc"T)
(43)
if the factors exp[+ UJkltT] and exp[+ U2/kBT] are not correlated, e.g. if Ui and
U2 operate on different coordinates and are therefore not coupled. Thus, even if
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the Hamiltonian of a system can be approximated by a linear combination of
terms, it is generally not possible to associate each term with a given free energy.
If we expand both the exponential functions in (42) in terms of Hl and H2 and
also use a Taylor expansion for the In function, we find
F = <#,> + <tft> + (kB Ty1 [<U, U2)-<!/,><C7a>] + O[(kB T)~2]
= ^ + £,-75. (44)
The free energy can be expressed as a sum of energy components and a term
containing all first and higher order correlations between H1 and H2, which
represents the entropy of the system. The extent to which this term can be further
separated is dependent on the degree to which the degrees of freedom of the
system are correlated (Smith & van Gunsteren, 19946).
In a number of recent studies an analysis of free energy components based on
the thermodynamic integration technique has been presented (Kuczera et al.
1990; Tidor & Karplus, 1991; Simonson & Brunger, 1992; Miyamoto &
Kollman, 1993; Prod'hom & Karplus, 1993), which is based on the formula
j jdHliP'1"'
n d A
e-f«iU>.'-;A)+H,(p,r;
(2). (45)
Formula (45) shows that the value of the components AFBA(i) and AFBA(2) will
depend on the chosen A-dependence of the Hamiltonian, which defines the
pathway connecting system A with system B. This choice of pathway is not
unique, and hence the free energy components calculated using (45) are not
unique. A detailed analysis of free energy components based on (45) is, therefore,
meaningless (Shi et al. 1993; Mark & van Gunsteren, 1994 a).
4.2.6 Free energy changes by extrapolation
In terms of practical drug design the prediction of the relative free energy of
binding of a single modified inhibitor will be of little use. It will, in almost all
cases, be more efficient to synthesize and test the modified compound
experimentally. The prediction of free energy trends for a large number of
possible changes of the inhibitor would, in contrast, be of considerable help in
guiding synthetic choices. This would be true as long as a range of modifications
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could be treated in a single calculation and the calculation possesses reasonable
predictive power. Such a method has been proposed recently (Gerber et al. 1993;
Smith & van Gunsteren, 1994 a).
If one is interested in the relative binding constant of a series of M different
inhibitors / j , / 2 , . . . ,/M to an enzyme E, one would use (M-i) thermodynamic
cycles (35)
(exp.)
£+/, > (£://)
(sim.) I |(sim.)
• (exp.) •
E+I2 ) (E:I2)
(sim.) I |(sim.) (46)
(sim.) I j(sin,)
E+1M •(£:/«)
The (M-i) relative free energy differences of binding can be obtained from
simulating the 2(M-i) vertical processes in (46).
The free energy change in each vertical process can be obtained using the
thermodynamic integration formula
-IF(Im+1)-F(IJ=\ F'(A)dA (47)
using (34) or higher-order derivatives of F(X) (Smith & van Gunsteren, 19940).
This is computationally costly, when the change of A for each different process is
separately carried out to compute (47). A considerable reduction of computational
effort can be achieved by using for F'(X) in (47) an extrapolation from the point
A = Am (van Gunsteren et al. 1993),
+ F<"'(Am) (A - Aro)n-V(« - 1 ) ! + ... (48)
which yields
S ^ " ' ( A J [Am + 1-AJ«/n! (49)
n - l
Using (49) the free energy change in each vertical process in (46) is obtained using
one A-value, so by performing only one simulation to obtain < ... )A -Of course,
accuracy is lost using the approximation (49). However, the extrapolation formula
(49) allows a further reduction of the computational effort in cases where the M
inhibitors differ only slightly from each other: one inhibitor, say Ilt is selected to
be simulated, and the free energy change to all other inhibitors Im is computed
using the extrapolation
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= I F<n>(A1)[Am-A1]n/K! (50)
n - l
for m = 2,3,... M. Using (50) instead of (47) reduces the computational effort by
about a factor MNk, where iVA is the number of A-values used in the numerical
integration of (47).
This idea has been tested by Gerber et al. (1993) using only first derivatives
F'(Aj) in (50). The use of the second and third derivatives F"^) and
F'"(Aj) in (50) improves the extrapolation approximation considerably in the case
of dipolar changes in an aqueous environment (Smith & van Gunsteren, 1994 a).
5. OUTLOOK
From a biophysical point of view drug design involves the optimisation or
minimisation of the interaction between, in general, complex molecules in
different molecular environments. The basic physical laws governing the
behaviour of molecular systems are known: quantum and classical statistical
mechanics. The formulae that express the free energy or entropy of a molecular
system in terms of its Hamilton function or operator, or classically spoken its
potential energy function, are available. The problem is, only, that the molecular
systems of interest to drug design contain far too many degrees of freedom to
handle exactly in terms of quantum or classical statistical mechanics. This leads
to the necessity to make simplifying assumptions concerning the influence and
importance of degrees of freedom, and to use approximations to the basic physical
laws and to the nature of atomic interactions.
From a historical point of view drug design has evolved from establishing
simple empirical relations between experimentally observed drug activity of
specific molecules and particular physical or chemical properties of these
molecules. With the advent of X-ray crystallography 3-dimensional structures of
molecules became available which allowed for a correlation between drug activity
and spatial molecular structure. The availability of molecular structures also
offered the possibility to compute molecular energies, and so laid the bridge
between fundamental physical calculations of (free) energies based on atomic and
electronic degrees of freedom on the one hand, and molecular physical properties
and the associated drug activity on the other hand.
The field of drug design on a molecular basis lies between two poles: (i) the
detailed modelling of atomic and electronic degrees of freedom of molecular
complexes based on fundamental physical laws, and (ii) the derivation of empirical
models that relate a number of molecular properties to a large body of
experimental observations using statistical methods to optimize the few model
parameters.
Which are the forces driving the development of the methodology used in
molecular drug design ? Firstly, there is the still increasing number of molecular
and protein 3-dimensional structures that become available each year from X-ray
crystallography and multi-dimensional NMR spectroscopy. The databases of
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molecular and protein structures contain a wealth of information that will be used
more and more routinely in the drug design process when the appropriate software
to extract and process the requested information becomes available and easy to
use. Secondly, the rapid and continuing increase of computing power at constant
price allows for the application of more and more complex and detailed molecular
modelling techniques in the process of drug design. Last but not least, the
development of drug design methodology is driven by demands of the drug
market due to emerging new diseases and the decreased activity of established
compounds against certain diseases.
These driving forces will partly determine the direction in which the
methodology will develop and be applied. Database approaches will become more
popular, and will be more widely used to derive empirical models based on
statistical analysis of cause-effect relations. At the fundamental side the quantum
mechanical treatments will cover larger molecules and include environmental
effects in an average manner. Classical simulations based on semi-empirical force
fields will be routinely used to study flexible molecular complexes and the
associated entropic effects. The accuracy of such simulations will be enhanced by
the steady improvement of the force fields used and the algorithms that are applied
when searching and sampling conformational space. These improved force fields
and molecular models will in turn be used in the empirical modelling of the
relations between molecular properties and experimental data regarding drug
activity.
Summarizing, we expect that both complex fundamental physical molecular
modelling techniques and simple empirical models based on statistical analysis of
experimental data concerning drug activity will continue to be developed. The
drug designer will continue to have to choose between complex physically based
methods which are relatively accurate, but too expensive or slow to be used in
practice on the one hand, and simple empirical rule based models which are cheap
and fast, but often not sufficiently accurate on the other hand. In other words she
will continue to sail between the Scylla of using a too detailed and complex
molecular model that does not give a timely answer at reasonable costs, and the
Charybdis of neglecting too many degrees of freedom in a simple model that gives
a quick and cheap answer which is useless due to its lack of accuracy.
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